Get the Stockscreener App
55.00
5.21%
-3.02
After Hours:
55.08
0.08
+0.15%
Dexcom Inc stock is traded at $55.00, with a volume of 10.94M.
It is down -5.21% in the last 24 hours and down -16.70% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$58.02
Open:
$58.015
24h Volume:
10.94M
Relative Volume:
1.88
Market Cap:
$21.57B
Revenue:
$4.30B
Net Income/Loss:
$571.50M
P/E Ratio:
38.50
EPS:
1.4285
Net Cash Flow:
$570.80M
1W Performance:
-5.53%
1M Performance:
-16.70%
6M Performance:
-34.01%
1Y Performance:
-20.19%
1-Day Range:
$54.11
$58.25
1-Week Range:
$54.11
$62.39
52-Week Range:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
55.00 | 22.63B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
126.36 | 217.27B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
100.02 | 146.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
356.03 | 135.31B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
92.20 | 115.51B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.39 | 47.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DXCM CLASS REMINDER: DexCom, Inc. Investors with Losses May have been Affected by Fraud – Contact BFA Law by December 26 Legal Deadline - GlobeNewswire Inc.
DexCom (NASDAQ:DXCM) Hits New 12-Month Low After Analyst Downgrade - Defense World
Lost Money on DexCom, Inc. (DXCM)? Contact Levi & Korsinsky Before December 26, 2025 to Join Class Action - ACCESS Newswire
Why TAL Education, Shake Shack And DexCom Just Appeared On Value Investors' Radars - Benzinga
DexCom Inc. stock outlook for YEAR2025 Volume Leaders & Low Drawdown Momentum Trade Ideas - newser.com
DexCom (DXCM) Analyst Ratings: Argus Research Lowers Price Targe - GuruFocus
DexCom, Inc. Class Action: Levi & Korsinsky Reminds DexCom, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of December 26, 2025DXCM - NewMediaWire
Levi & Korsinsky Urges DexCom, Inc. (DXCM) Shareholders to Act Before Lead Plaintiff Deadline December 26, 2025 - ACCESS Newswire
DXCM SECURITIES REMINDER: Lose Money on DexCom, Inc.? You Have Rights And Are Notified to Contact BFA Law Before December 26 Deadline - ACCESS Newswire
DexCom Inc. stock underperforms Friday when compared to competitors - MSN
DexCom, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before December 26, 2025 to Discuss Your RightsDXCM - MarketScreener
DexCom, Inc. (DXCM) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 26, 2025 Deadline - ACCESS Newswire
Key facts: Class action lawsuit filed against DexCom; price target cut to $90 - TradingView
Argus Research Adjusts DexCom Price Target to $90 From $100 - MarketScreener
DexCom, Inc. (DXCM) Stock forecasts - Yahoo Finance UK
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
DexCom, Inc. (DXCM) Stock Forecasts - Yahoo! Finance Canada
DexCom stock hits 52-week low at $56.44 amid market challenges By Investing.com - Investing.com South Africa
DexCom stock hits 52-week low at $56.44 amid market challenges - Investing.com Canada
DEXCOM CLASS ACTION LAWSUIT: DexCom, Inc. (NASDAQ:DXCM) - GlobeNewswire
Statistical indicators supporting DexCom Inc.’s strength2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Arkadios Wealth Advisors Acquires Shares of 2,485 DexCom, Inc. $DXCM - Defense World
Investors Who Lost Money on DexCom, Inc. (DXCM) Should Contact Levi & Korsinsky About Pending Class ActionDXCM - NewMediaWire
Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ) - DexCom Investor Relations
Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ) (2025-11-06) - Seeking Alpha
ROSEN, SKILLED INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionDXCM - MarketScreener
Kaplan Fox Alerts Investors of DexCom, Inc. (DXCM) to a Securities Class Action Deadline on December 26, 2025 - NewMediaWire
DexCom (DXCM): Assessing Valuation After Surge in Lawsuits Over Device Safety and Reliability - Yahoo Finance
Key facts: Class action lawsuit filed against DexCom; strong demand reported - TradingView
Shareholders SueWallSt in New Class Action Against DexCom, Inc.Act Now - Nasdaq
Class Action Announcement for DexCom, Inc. (DXCM): Kessler - GlobeNewswire
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. InvestorsLead Plaintiff Deadline December 26, 2025 - ACCESS Newswire
Will DexCom Inc. stock continue dividend increasesMarket Sentiment Review & Safe Capital Growth Stock Tips - newser.com
Did You Lose Money on DexCom, Inc. (DXCM)? Levi & Korsinsky Urges Investors to Act Before December 26, 2025 - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of DexCom, Inc. Investors - GlobeNewswire
Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for InvestorsContact The Gross Law Firm - MarketScreener
What MACD trends signal for DexCom Inc. (DC4) stockJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Is DexCom Inc. (DC4) stock a top pick for value investorsTrend Reversal & Low Risk Entry Point Guides - newser.com
We Like DexCom's (NASDAQ:DXCM) Earnings For More Than Just Statutory Profit - Yahoo Finance
Has DexCom Inc. found a price floorJuly 2025 Analyst Calls & Accurate Intraday Trade Tips - newser.com
Will a bounce in DexCom Inc. offer an exitTrade Signal Summary & Safe Investment Capital Preservation Plans - newser.com
What catalysts could drive DexCom Inc. stock higherJuly 2025 Patterns & Daily Technical Stock Forecast Reports - newser.com
Can technical indicators confirm DexCom Inc.’s reversalEntry Point & AI Forecasted Entry/Exit Points - newser.com
The 5 Most Interesting Analyst Questions From DexCom’s Q3 Earnings Call - Yahoo Finance
Will DexCom Inc. stock maintain momentum in 2025July 2025 Trends & Weekly Return Optimization Alerts - newser.com
Securities Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)Levi & Korsinsky Represents Shareholders - ACCESS Newswire
Class Action Lawsuit Alert: Levi & Korsinsky Reminds DexCom, Inc. (DXCM) Investors of December 26, 2025 Deadline - ACCESS Newswire
Lost Money on DexCom, Inc. (DXCM)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - NewMediaWire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionDXCM - MarketScreener
Contact The Gross Law Firm by December 26, 2025 Deadline to Join Class Action Against DexCom, Inc.(DXCM) - GlobeNewswire
DXCM: Kirby McInerney LLP Advises DexCom, Inc. Investors of Class Action Lawsuit - GlobeNewswire
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):